Welcome to our dedicated page for BELITE BIO SEC filings (Ticker: BLTE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Belite Bio, Inc. filings document foreign-issuer disclosures for a clinical-stage biopharmaceutical company developing tinlarebant for degenerative retinal diseases. Form 6-K reports furnish press releases on clinical-trial progress, FDA-related regulatory updates, financial results, annual-report availability, material agreements, shareholder matters, and capital-structure activity involving American Depositary Shares.
The company's Form 20-F reporting framework covers audited consolidated financial statements and public-company disclosure for BLTE as a foreign private issuer. Its filing record centers on STGD1, geographic atrophy in advanced dry AMD, tinlarebant development, financing activity, governance matters, and the incorporation of furnished reports into effective Securities Act registration statements.
Belite Bio Chief Scientific Officer Nathan L. Mata executed pre-planned open-market sales of 1,000 American depositary shares. On May 4, 2026, he sold ADS in multiple trades between weighted average prices of about $153 and $158, as detailed in the filing.
The sales were carried out under a Rule 10b5-1 trading plan that Mata adopted on December 10, 2025, indicating they were scheduled in advance rather than timed discretionarily. Following these transactions, he directly holds 2,666 ADS of Belite Bio.
Belite Bio Chief Scientific Officer Nathan L. Mata reported open-market sales of company stock. On May 1, 2026, he sold a total of 1,000 American depositary shares (ADS), with each ADS representing one ordinary share of Belite Bio.
The sales were executed in multiple trades at prices ranging from about $153.8 to $160 per ADS and were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025. The filing does not show any option exercises or derivative transactions alongside these sales.
Belite Bio Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares of the company in open-market transactions. The sales occurred on April 30, 2026 at weighted average prices reported between $155.62 and $158.42 per share.
These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025. Following the sales, Mata directly holds 4,666 American depositary shares of Belite Bio, Inc.
Belite Bio Chief Scientific Officer Nathan L. Mata sold a total of 1,000 American depositary shares in open-market transactions on April 29, 2026. The sales occurred at weighted average prices ranging from about $154.22 to $158.21, according to the filing footnotes.
The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025. After these sales, Mata directly holds 5,666 ADS of Belite Bio.
Belite Bio Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares (ADS) of BELITE BIO, INC in open-market transactions on April 28, 2026. The ADS were sold in multiple small trades at weighted average prices ranging from $154.62 to $162.59 per ADS.
The sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted by the executive on December 10, 2025, indicating they were scheduled in advance. Following these transactions, he directly owned 6,666 ADS of the company.
Belite Bio Chief Scientific Officer Nathan L. Mata reported selling a total of 1,000 American depositary shares in open-market transactions. The sales occurred on April 27, 2026 at prices ranging from about $160.83 to $164.07 per share. Following these trades, he directly holds 7,666 American depositary shares, each representing one ordinary share of Belite Bio. The filing notes that the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on 12/10/2025, indicating the sales were scheduled in advance rather than timed discretionarily.
Belite Bio chief scientific officer Nathan L. Mata reported open‑market sales of 1,000 American depositary shares (ADS) of the company. The transactions occurred on April 24 and were executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on December 10, 2025.
The ADS were sold in multiple trades at prices including $162.53 and various weighted average prices in the high‑$150s to low‑$160s. Following these sales, Mata directly owns 8,666 ADS, each representing one ordinary share of Belite Bio.
Belite Bio Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares of the company on April 23, 2026. The sales were open-market transactions at prices ranging from about $164 to $170 per ADS and were executed under a Rule 10b5-1 trading plan adopted on 12/10/2025.
BELITE BIO, INC director and CEO Yu-Hsin Lin reported a compensation-related share vesting. On 04/21/2026, 10,000 ordinary shares were delivered upon vesting of restricted stock units granted on September 15, 2025 after specified performance criteria were met.
Following this non-market transaction, Lin directly holds 182,949 ordinary shares. The event reflects equity-based compensation vesting rather than an open-market purchase or sale.
Belite Bio’s Chief Medical Officer, Hendrik Peter Scholl, reported the vesting of a performance-based stock option held indirectly through Bioptima Ltd. The option covers 10,000 ordinary shares at an exercise price of $77.40 per share.
The option was originally granted on October 7, 2025 and vested on April 21, 2026 after specified performance criteria were met. Following this vesting event, 10,000 stock option rights remain outstanding under this grant, with an expiration date of October 6, 2035. This filing reflects a compensation-related milestone rather than an open-market share purchase or sale.